Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 348 followers
Latest posts
Last updated about 21 hours ago
Reminder: Invitation to Roche’s Diagnostics Day 2025
about 21 hours ago
The Roche Investor Relations team would like to invite you to the...
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
3 days ago
Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets)...
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
9 days ago
Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and...
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
10 days ago
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter
15 days ago
Group sales grew by 6%1 at constant exchange rates (CER; 7% in...
Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
17 days ago
USD 50 billion commitment includes new state-of-the art research and development (R&D)...
Reminder: Invitation to Roche’s First Quarter Sales 2025 Presentation
22 days ago
Roche will publish its Sales Results for the 1st Quarter 2025 prior...
Invitation to Roche’s Diagnostics Day 2025
24 days ago
The Roche Investor Relations team would like to invite you to the...
European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
25 days ago
Approval based on Phase III STARGLO study where Columvi in combination with...
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
about 1 month ago
New trontinemab data continue to support rapid and deep, dose-dependent reduction of...
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
about 1 month ago
MUSETTE trial was designed to determine whether a higher dose of the...
Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)
about 1 month ago
Roche has received the validation of its near-term and long-term greenhouse gas...